FFA and LDOM Supplementary Figure

Supplemental Figure 1: FFA patient with occipital hairline regrowth with low-dose oral minoxidil (LDOM) 1.25 mg daily. FFASI 3-point decrease from baseline (A) to follow-up 6.6 months (B). Prior therapeutic regimen included hydroxychloroquine 200 mg PO bid, intralesional triamcinolone 2.5 mg/mL, platelet rich plasma (2 sessions), and topical minoxidil 5%, and was maintained throughout study interval.